In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroPharma Inc.

http://www.viropharma.com

Latest From ViroPharma Inc.

How Sweden's Calliditas Built Up Its US Presence And Development Portfolio

Interview: delivering on its US business strategy during the COVID-19 pandemic has required a focus on communication, according to Calliditas CEO Renee Aguiar-Lucander.

Renal Business Strategies

Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds

Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns. 

Financing StartUps and SMEs

Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations

Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.

Deals Business Strategies

Retrophin Bolsters Portfolio With Orphan Technologies Buyout

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

Deals M & A
See All

Company Information

  • Other Names / Subsidiaries
    • Auralis Limited
    • DuoCort Pharma AB
    • Lev Pharmaceuticals, Inc.
UsernamePublicRestriction

Register